The extracellular domain of HER2 is unable to bind extracellular ligands and depends on heterodimerization with other ligand-activated receptors like EGFR. 3 ...the combination of lapatinib plus ...
So trastuzumab binds to domain IV of the extracellular domain of HER2, and it triggers a tumor-suppressive action through multiple mechanism, including activation of antibody-dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback